Parkinson's disease, levodopa-use and the risk of melanoma

Abstract Since the early 1970s, the literature has suggested an association between Parkinson's Disease (PD) and/or levodopa-use and an increased risk for the development of malignant melanoma. In some countries, this possible association has even led to a warning in the drug insert leaflet of...

Full description

Saved in:
Bibliographic Details
Published in:Parkinsonism & related disorders 2009-09, Vol.15 (8), p.551-553
Main Authors: Vermeij, J.-D, Winogrodzka, A, Trip, J, Weber, W.E.J
Format: Article
Language:English
Subjects:
Animals
Humans
Levodopa
Levodopa - adverse effects
Melanoma
Melanoma - chemically induced
Melanoma - epidemiology
Melanoma - etiology
Neurology
Parkinson Disease - complications
Parkinson Disease - drug therapy
Parkinson Disease - epidemiology
Parkinson's Disease
Risk Factors
Skin Neoplasms - chemically induced
Skin Neoplasms - epidemiology
Skin Neoplasms - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Since the early 1970s, the literature has suggested an association between Parkinson's Disease (PD) and/or levodopa-use and an increased risk for the development of malignant melanoma. In some countries, this possible association has even led to a warning in the drug insert leaflet of the possible risk. Recently, five studies have been published that have investigated both associations and three conclusions can be drawn. Firstly, there appears to be an increased risk in the development of melanomas in patients with PD. Secondly, this increased risk is already present before the PD is diagnosed. Finally, it is unlikely that levodopa plays any role in this phenomenon. It is not known which factors are responsible for this increase in the development of melanomas in PD patients and this needs further investigation. We recommend the removal of the warning from the drug insert leaflet, since this can lead to unnecessary fear on the part of the patients and physician resistance to prescribing this medication.
ISSN:1353-8020
1873-5126
DOI:10.1016/j.parkreldis.2009.05.002